Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Hepatology

Volumn 60, Issue 5, 2014, Pages 1697-1707

  Kudo, Masatoshi ^a   Han, Guohong ^b   Finn, Richard S ^c   Poon, Ronnie T P ^d   Blanc, Jean Frederic ^e   Yan, Lunan ^f   Yang, Jijin ^g   Lu, Ligong ^h   Tak, Won Young ⁱ   Yu, Xiaoping ^j   Lee, Joon Hyeok ^k   Lin, Shi Ming ^l   Wu, Changping ^m   Tanwandee, Tawesak ⁿ   Shao, Guoliang ^o   Walters, Ian B ^p   Dela Cruz, Christine ^p   Poulart, Valerie ^p   Wang, Jian Hua ^q  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f SICHUAN UNIVERSITY   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

ⁱ Kyungpook National University Hospital   (South Korea)

^j HUNAN CANCER HOSPITAL   (China)

^k Sungkyunkwan University School of Medicine   (South Korea)

^l CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^m THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

ⁿ MAHIDOL UNIVERSITY   (Thailand)

^o ZHEJIANG CANCER HOSPITAL   (China)

^p BRISTOL MYERS SQUIBB   (United States)

^q ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BRIVANIB; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; THYROTROPIN; ALANINE; FIBROBLAST GROWTH FACTOR RECEPTOR; TRIAZINE DERIVATIVE; VASCULOTROPIN A;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PERITONITIS; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPONATREMIA; HYPOTHYROIDISM; INSOMNIA; INTENTION TO TREAT ANALYSIS; LEUKOCYTE DISORDER; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTE DISORDER; THYROTROPIN BLOOD LEVEL; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VOMITING; ADJUVANT CHEMOTHERAPY; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; LIVER NEOPLASMS; MIDDLE AGED; TREATMENT FAILURE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, FIBROBLAST GROWTH FACTOR; TREATMENT FAILURE; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84922252607     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27290     Document Type: Article

References (27)

1. Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39:503-509.
2. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
3. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
4. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010;30:258-270.
5. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol 2003;9:2445-2449.
6. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009;100:1385-1392.
7. Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008;99:2037-2044.
8. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914-921.
9. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004;10:2878-2882.
10. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001;182:298-304.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
12. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
13. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-f][1, 2, 4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008;51:1976-1980.
14. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14:6146-6153.
15. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 2010;9:369-378.
16. Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011;17:5299-5310.
17. Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2090-2098.
18. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17:1973-1983.
19. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115.
20. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
21. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
22. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-413.
23. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517-3524.
24. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516.
25. Lencioni M, Llovet JM, Han G, Tak WY, Yang J, Leberre MA, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. [Abstract]. J Clin Oncol 2012;30(Suppl.);LBA154.
26. Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8:1743-1749.
27. Kudo M, Imanaka K, Chiba N, Nakachi K, Tak WT, Takayama T, et al. Phase III study of Sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117-2127.